Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Today, the CATCH ME consortium (Characterizing Atrial fibrillation by Translating its Causes into Health Modifiers in the Elderly) was launched at the European Society of Cardiology office in Brussels.
Brussels, 21 May 2015. Today, the CATCH ME consortium (Characterizing Atrial fibrillation by Translating its Causes into Health Modifiers in the Elderly) was launched at the European Society of Cardiology office in Brussels. CATCH ME brings together 6 academic expert institutes, 3 healthcare organisations and 2 leading professional organisations with the intention to improve the care of patients with atrial fibrillation (AF). Horizon 2020, which is the largest EU research and innovation programme, supports the consortium with a 5 Million Euro grant over 4 years.2% of the European population, and 12-15% of Europe’s octogenarians suffer from atrial fibrillation (AF) (1), a cardiac disease putting them at risk for stroke, cognitive decline, heart failure, and premature death. CATCH ME aims to improve the prevention and treatment of atrial fibrillation and its complications. The goal is to develop and validate better disease management strategies based on the improved understanding of the main health modifiers (such as genes, drugs, and behaviour) leading to atrial fibrillation in the European population. More specifically, CATCH ME will: 1. Identify the major health modifiers causing AF in the Elderly in Europe, 2. Develop clinical tools that will personalise the prevention and management of AF patients, and3. Guide and strengthen future strategies to prevent, diagnose, and treat AF in Europe.CATCH ME also aims at providing substantial answers to current AF uncertainties such as gender differences, by elucidating the reasons why female European citizens seem to be better protected against AF compared to males, or why females are at higher stroke risk than males once they have developed AF. Beyond evidence generation and therapy recommendations, CATCH ME will combine its research excellence with the knowledge transfer and communication competence of the European Society of Cardiology (ESC) and the Atrial Fibrillation NETwork (AFNET) for the result dissemination. The consortium is working closely together with a global leader in in-vitro diagnostics tests (Roche Professional Diagnostics) who will support the development of existing and novel intellectual property in the consortium into marketable tests. Thus, CATCH ME will generate tangible and sustained improvements in the prevention and management of AF patients in Europe.CATCH ME will propose the novel AF classification to researchers, health care professionals, and patients throughout Europe. This will be realized by solid scientific underpinning of the clinical tools, educational programmes, and by world-wide provision of CATCH ME apps that can be used on any smart phone.
The CATCH ME partners combine excellence in clinical practice, translational pathophysiology, genetics, bioengineering, epidemiology and biostatistics with competence in the development of cardiovascular practice guidelines. As a consortium, CATCH ME also has access to large sets of human biological specimens (atrial tissue and blood samples) and carefully phenotyped patient populations. This is the basis to define the major causes and risk factors (“health modifiers”) of AF in Europe and characterise distinct clinical types of AF to advance future personalised strategies for prevention, diagnosis, and treatment of AF patients.The consortium is led by Professor Paulus Kirchhof from the University of Birmingham (UK) and consists of the following 9 partners:University of Birmingham (UK), Paulus Kirchhof and Larissa FabritzUniversidad de Barcelona (Spain), Lluis Mont and Eduard GuaschMaastricht University (Netherlands), Ulrich Schotten, Monika Stoll, Harry Crijns and Stef ZeemeringLudwig-Maximilians University Munich (Germany), Moritz Sinner, Reza Wakili and Stefan Kääb University of Oxford (UK), Barbara Casadei and Charis AntoniadesUniversité Pierre Marie Curie (France), Stéphane Hatem Atrial Fibrillation Network (Germany), Gerlinde Benninger and Günter BreithardtEuropean Society of Cardiology (France)UK Health & Environment Research Institute (UK), David Cartlidge and Andy WestFor further information please go here ENDS
(1) ESC Guidelines for the management of Atrial Fibrillation here
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.About AFNETThe Atrial Fibrillation Network association (AFNET) is an interdisciplinary research network comprising scientists and physicians from hospitals and practices dedicated to improving the management of atrial fibrillation through coordinated research in Germany and Europe. Its main objective is to conduct high quality investigator-initiated clinical trials and registries on a national and international level. About Horizon 2020Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges.About Catch MECatch me is a consortium of 6 academic expert institutes, 3 healthcare organisations and 2 leading professional organisations with the intention to improve the care of patients with atrial fibrillation (AF). . Its aim is to improve the prevention and treatment of atrial fibrillation and its complications
© 2017 European Society of Cardiology. All rights reserved